Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29278748 | 0.92 | MEN1 (0.33) | NPSR1LMNAMEN1KMT2A | |
| SCHEMBL12919608 | 0.82 | NPSR1 (0.41) | NPSR1LMNAMEN1KMT2ATSHR | |
| SCHEMBL15313392 | 0.80 | NPSR1 (0.39) | NPSR1LMNAMEN1KMT2AMAPT | |
| SCHEMBL26967968 | 0.76 | NPSR1 (0.34) | NPSR1LMNAMEN1KMT2AMAPT | |
| SCHEMBL26967985 | 0.76 | NPSR1 (0.34) | NPSR1LMNAMEN1KMT2AMAPT | |
| SCHEMBL26967964 | 0.73 | CYP3A4 (0.36) | NPSR1LMNAMEN1KMT2ATSHR | |
| SCHEMBL11785043 | 0.72 | — | — | |
| SCHEMBL13769770 | 0.72 | CYP4F2 (0.35) | NPSR1LMNATSHR | |
| SCHEMBL21777770 | 0.71 | MEN1 (0.33) | NPSR1LMNAMEN1KMT2AMAPT | |
| SCHEMBL26967988 | 0.70 | MEN1 (0.33) | NPSR1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360125-A9 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-10-31 | — | — | US | disclosed |
| US-20240150353-A1 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | UNIV PRINCETON (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117500778-A | 2-substituted bicyclo [1.1.1] pentanes | 普林斯顿大学保管委员会 | 2024-02-02 | — | — | CN | disclosed |
| EP-4294784-A1 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | The Trustees of Princeton University (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022178559-A1 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360125-A9 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | CYP1B1, BMP2, CCR1 | NPSR1 1855/4885LMNA 1409/4885MEN1 2139/4885 |
| US-20240150353-A1 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | CYP1B1, BMP2, CCR1 | NPSR1 1855/4885LMNA 1409/4885MEN1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.